Absci Shares Rise 27% After Announcing Collaboration With AstraZeneca
04 Dicembre 2023 - 4:41PM
Dow Jones News
By Chris Wack
Absci shares were up 27% at $2.21 after the company entered into
a collaboration with AstraZeneca to deliver an AI-designed antibody
against an oncology target.
The stock hit its 52-week low of $1.11 on Oct. 26, and is down
18% in the past 12 months.
Absci said this collaboration combines its Integrated Drug
Creation platform with AstraZeneca's expertise in oncology with the
goal of speeding up the discovery of a potential new cancer
treatment candidate.
Absci will contribute its generative AI technology to deliver a
therapeutic candidate antibody for a specified oncology target. The
agreement includes an upfront commitment, R&D funding and
milestone payments, in addition to royalties on product sales.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
December 04, 2023 10:26 ET (15:26 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Grafico Azioni AbSci (NASDAQ:ABSI)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni AbSci (NASDAQ:ABSI)
Storico
Da Giu 2023 a Giu 2024